Top Stories

BeiGene reports positive Phase III interim analysis for lung cancer drug

Interim results from a Phase III clinical trial have shown that patients receiving a cancer immunotherapy drug for a form of lung cancer on top of chemotherapy were more likely than those receiving chemotherapy alone to survive without their disease worsening, the company developing the drug said Monday. Beijing-based BeiGene reported an improvement in progression-free […]